EGFR and non-small cell lung carcinoma: This ongoing study will further evaluate long-term survival outcome, testifying to the role of tumor-informed MRD detection during the perioperative period and verifying the value of pretreatment immune phenotype in selecting potential beneficiaries of immunotherapy in EGFR-mutant NSCLC.